Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 228

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 228
---
 the independence requirements contemplated by Rule 10A-3 under the Exchange Act. The Supervisory Board has further determined that Pascale Boissel is an “audit committee financial expert” as defined by the Nasdaq listing rules and that each of the members qualifies as financially sophisticated under the Nasdaq Listing Rules.

The principal responsibility of the Audit Committee is to monitor the existence and efficacy of the financial audit and risk control procedures on an ongoing basis, and the Audit Committee charter is contained in the Supervisory Board’s charter.

Innate's Supervisory Board has specifically assigned the following duties to the Audit Committee:

• legal control of the half-year and annual accounts;

• evaluating internal control practices, risk analysis;

• supervising the creation of the financial statements published by us;

• assessing accounting methods; and

• selecting statutory auditors, negotiating their fees, reviewing of their conclusions and reviewing their independence.

The Audit Committee reviews and approves the report from the Chairman of the Supervisory Board on internal control.

Compensation and Nomination Committee

Innate's Compensation and Nomination Committee assists the Supervisory Board in reviewing and making recommendations to the Supervisory Board with respect to the appointment and the compensation of the members of the Executive Board, Supervisory Board and Leadership Team and other key

employees. In accordance with the Compensation and Nomination Committee charter contained in the Supervisory Board's charter, the Compensation and Nomination Committee is composed of at least two members appointed by the Supervisory Board. As of December 31, 2024, the members of the committee are Pascale Boissel, Irina Staatz-Granzer, Véronique Chabernaud and Jean-Yves Blay. The Company's Supervisory Board has determined that Pascale Boissel, Irina Staatz-Granzer, Véronique Chabernaud and Jean-Yves Blay are independent within the meaning of the applicable Nasdaq listing rules and the independence requirements contemplated by Rule 10A-3 under the Exchange Act.

The Company's Supervisory Board has specifically assigned the following duties to the Compensation and Nomination Committee:

• reviewing the remuneration policy, in particular the description of the collective objectives (applicable company-wide) and individual objectives (for members of the Executive Board and the Leadership Team);

• reviewing the compensation of the members of the Executive Board and the Leadership Team, the policy concerning the distribution of equity such as warrants, stock options, grants and capital increases reserved for members of the savings plan, examining the amount